90 related articles for article (PubMed ID: 2287063)
1. [Plasminogen activator in leukemic cell homogenate].
Wada H; Ogasawara Z; Kumeda Y; Tamaki S; Tanigawa M; Takagi M; Iwasaki E; Mori Y; Deguchi A; Tsukada T
Rinsho Ketsueki; 1990 Nov; 31(11):1794-9. PubMed ID: 2287063
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators and their inhibitors in leukemic cell homogenates.
Wada H; Kumeda Y; Ogasawara Z; Ohiwa M; Kaneko T; Tamaki S; Ohno T; Kageyama S; Kobayashi T; Deguchi K
Am J Hematol; 1993 Feb; 42(2):166-70. PubMed ID: 8438877
[TBL] [Abstract][Full Text] [Related]
3. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Fukao H; Yamamoto K; Matsuo O
Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
[TBL] [Abstract][Full Text] [Related]
4. [Activity of procoagulant and fibrinolysis in homogenate of leukemic cells].
Wada H; Tanigawa M; Suzuki H; Takagi M; Mori Y; Ohno T; Kita K; Kobayashi T; Deguchi K; Shirakawa S
Rinsho Ketsueki; 1989 Oct; 30(10):1783-7. PubMed ID: 2593244
[TBL] [Abstract][Full Text] [Related]
5. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
6. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations.
Francis RB; Seyfert U
J Lab Clin Med; 1987 Nov; 110(5):541-7. PubMed ID: 3117952
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
11. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
12. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
13. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
14. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
16. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
17. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
Sakata Y; Murakami T; Noro A; Mori K; Matsuda M
Blood; 1991 May; 77(9):1949-57. PubMed ID: 1708294
[TBL] [Abstract][Full Text] [Related]
18. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
20. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
